Technology area: Biotechnology & Pharmaceuticals
31 pending office actions • 31 art units • 31 examiners • 0 of 31 (0%) have an AI response strategy ready • 38 patents granted in the last 365 days
Technion Research And Development Foundation Limited has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, showing that the company's innovations are being reviewed by several different specialized groups. The portfolio involves 3 distinct examiners, which means that every pending office action is currently assigned to a unique individual.
MERRIAM, AARON ROGERS is the busiest examiner for this portfolio, with 1 pending office action currently assigned. This indicates that there is no concentration of cases under a single examiner, as the number of 3 distinct examiners is equal to the total number of 3 pending office actions. Prosecution teams must prepare for 3 different sets of examiner feedback and procedural styles.
The 3 distinct art units involved suggest that the company's technology covers a variety of sub-sectors within the biotechnology field. Managing 3 pending office actions across these different units requires a versatile approach to patent response. Because each of the 3 pending actions is with a different examiner, the company faces a decentralized prosecution landscape.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §101 + other | 7 (23%) |
| §103 only | 10 (32%) |
| §112 only | 3 (10%) |
| Double-patenting only | 1 (3%) |
| Double-patenting + other | 1 (3%) |
| Multi-statute (no §101) | 8 (26%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUON, VIRAK | 1 | 83.7% | +18.8% |
| RUBY, TRAVIS C | 1 | 54.0% | +27.2% |
| VELEZ, ROBERTO | 1 | 67.5% | +21.6% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| TANINGCO, MARCUS H | 1 | 81.0% | +6.6% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
| DARNELL, BAILEIGH K | 1 | 70.2% | +25.9% |
| VIGIL, TORIANA NICHOLE | 1 | 52.9% | +26.8% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19248948 | SYSTEM AND METHODS FOR FABRICATION OF CURED ARTICLES | NGUON, VIRAK | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17288539 | MACHINE LEARNING FOR PROTEIN IDENTIFICATION | SABOUR, GHAZAL | 30d overdue |
| 17780404 | MOLECULAR DATA STORAGE SYSTEMS AND METHODS | BAILEY, STEVEN WILLIAM | 30d overdue |
| 17050560 | A DEVICE AND METHOD FOR DETERMINING CELL INDENTATION ACTIVITY | CHIN, CHRISTOPHER L | 23d |
| 17936378 | Automatic classification of healthy and disease conditions from images or digital standard 12-lead ECGs | EVANISKO, GEORGE ROBERT | 26d |
| 18626620 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | ALLEY, GENEVIEVE S | 33d |
| 19137274 | ENHANCEMENT OF THE THERMOACOUSTIC EFFECT | RUBY, TRAVIS C | — |
| 18837691 | METHODS AND COMPOSITIONS FOR TREATING DIABETES | BERKE-SCHLESSEL, DAVID W | — |
| 18790246 | X-RAY SOURCES | TANINGCO, MARCUS H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18626620 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | ALLEY, GENEVIEVE S | 33d |
| 19248948 | SYSTEM AND METHODS FOR FABRICATION OF CURED ARTICLES | NGUON, VIRAK | — |
| 19137274 | ENHANCEMENT OF THE THERMOACOUSTIC EFFECT | RUBY, TRAVIS C | — |
| 19073091 | METHOD AND SYSTEM FOR ANALYZING GAS | VELEZ, ROBERTO | — |
| 18837691 | METHODS AND COMPOSITIONS FOR TREATING DIABETES | BERKE-SCHLESSEL, DAVID W | — |
| 18586768 | MICROPARTICLES MADE OF PLANT PROTEIN EXTRACTS AND USES THEREOF AS CELL CARRIERS FOR THE PREPARATION OF FOOD PRODUCTS | WESTON, ALYSSA G | — |
| 18421180 | ENCAPSULATED QUANTUM CONFINEMENT STRUCTURES AND METHOD OF FABRICATING SAME | DARNELL, BAILEIGH K | — |
| 18407721 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | VIGIL, TORIANA NICHOLE | — |
| Art Unit | Apps |
|---|---|
| 1742 | 1 |
| 3763 | 1 |
| 2858 | 1 |
| 1651 | 1 |
| 2884 | 1 |
| 1617 | 1 |
| 1633 | 1 |
| 1743 | 1 |
| 1612 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19248948 | SYSTEM AND METHODS FOR FABRICATION OF CURED ARTICLES | NGUON, VIRAK | 1742 | DP | Non-Final OA | — | Pending | Jun 25, 2025 |
| 19137274 | ENHANCEMENT OF THE THERMOACOUSTIC EFFECT | RUBY, TRAVIS C | 3763 | §102§103 | Non-Final OA | — | Pending | Jun 09, 2025 |
| 19073091 | METHOD AND SYSTEM FOR ANALYZING GAS | VELEZ, ROBERTO | 2858 | §103 | Non-Final OA | — | Pending | Mar 07, 2025 |
| 18837691 | METHODS AND COMPOSITIONS FOR TREATING DIABETES | BERKE-SCHLESSEL, DAVID W | 1651 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18790246 | X-RAY SOURCES | TANINGCO, MARCUS H | 2884 | §102§103 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18626620 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | ALLEY, GENEVIEVE S | 1617 | §102§103 | Final Rejection | 33d | Pending | Apr 04, 2024 |
| 18586768 | MICROPARTICLES MADE OF PLANT PROTEIN EXTRACTS AND USES THEREOF AS CELL CARRIERS FOR THE PREPARATION OF FOOD PRODUCTS | WESTON, ALYSSA G | 1633 | §102§103 | Final Rejection | — | Pending | Feb 26, 2024 |
| 18421180 | ENCAPSULATED QUANTUM CONFINEMENT STRUCTURES AND METHOD OF FABRICATING SAME | DARNELL, BAILEIGH K | 1743 | §103 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18407721 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | — | Pending | Jan 09, 2024 |
| 18569642 | COMPOSITIONS COMPRISING SPHERICAL PARTICLES AND USES OF SAME | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18522518 | PROTEINACEOUS ELECTRODE BINDER | WANG, PIN JAN | 1717 | §102§103 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18557588 | ESTIMATING PARAMETERS OF A MODEL THAT IS NON-LINEAR AND IS MORE COMPLEX THAN A LOG-LINEAR MODEL | ANDERSON, SCOTT C | 3694 | §101§103 | Final Rejection | — | Pending | Oct 27, 2023 |
| 18273357 | RNAI NANOPARTICLES AND METHODS OF USING SAME IN AGRICULTURE | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18214664 | METHODS OF NEURAL INHIBITION FOR TREATING BOWEL DISEASES AND DISORDERS | MATTHEWS, CHRISTINE HOPKINS | 3791 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 27, 2023 |
| 18196024 | COPLANAR HETEROJUNCTION MONOLITHIC DEVICE AND METHOD OF FABRICATING THE SAME | PROSTOR, ANDREW VICTOR | 2812 | §102§103 | Non-Final OA | — | Pending | May 11, 2023 |
| 18140177 | PREDICTING IMMUNOTHERAPY RESPONSE | DUNN, MCKENZIE A | 1678 | §112 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 18113522 | ULTRASENSITIVE RNA QUANTIFICATION USING NANOPORES | CHUNDURU, SURYAPRABHA | 1681 | §101§103 | Final Rejection | — | Pending | Feb 23, 2023 |
| 18008515 | UBIQUITIN HIGH AFFINITY PEPTIDES, AND METHODS OF USING SAME, AND IDENTIFYING SAME | BOWLES, DAVID PAUL | 1654 | §103§112Other | Final Rejection | — | Pending | Dec 06, 2022 |
| 17976084 | HARDWARE ARTIFICIAL NEURAL NETWORK (ANN) ANALOG CIRCUIT, AND METHOD OF USING THEREOF | BAKER, EZRA JAMES | 2126 | §103 | Final Rejection | 9d overdue | Pending | Oct 28, 2022 |
| 17887828 | UBIQUITIN LIGASE KPC1 PROMOTES PROCESSING OF P105 NF-KAPPAB1 TO P50, ELICITING STRONG TUMOR SUPPRESSION | CANELLA, KAREN A | 1643 | §112 | Non-Final OA | 21d | Pending | Aug 15, 2022 |
| 17501261 | SYSTEM AND METHOD FOR MULTI CHIRAL DETECTION | WISE, OLIVIA M. | 1685 | §103DP | Final Rejection | — | Pending | Oct 14, 2021 |
| 17602866 | FORMULATIONS FOR ENCAPSULATION AND BIOAVAILABILITY IMPROVEMENT OF BIOACTIVE COMPOUNDS BASED ON NATURAL PLANT BASED MATERIALS | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 33d | Pending | Oct 11, 2021 |
| 17288539 | MACHINE LEARNING FOR PROTEIN IDENTIFICATION | SABOUR, GHAZAL | 1686 | §101§103 | Non-Final OA | 30d overdue | Pending | Apr 25, 2021 |
| 17050560 | A DEVICE AND METHOD FOR DETERMINING CELL INDENTATION ACTIVITY | CHIN, CHRISTOPHER L | 1677 | §101§102§112 | Final Rejection | 23d | Pending | Oct 26, 2020 |
| 19104171 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | LEE, SIN J | 1613 | §112 | Non-Final OA | — | Pending | Feb 14, 2025 |
| 17918893 | DEVICE AND METHOD FOR GENERATING IMAGE AND DISTANCE INFORMATION | RODRIGUEZ, VICENTE M | 3642 | §103 | Non-Final OA | 16d overdue | Pending | Oct 13, 2022 |
| 17823933 | PROCESS FOR THE MANUFACTURING OF FERMENTED DAIRY PRODUCT SUBSTITUTES | DIVIESTI, KARLA ISOBEL | 1792 | §103 | Final Rejection | — | Pending | Aug 31, 2022 |
| 18044458 | OXYGEN INSENSITIVE AMPEROMETRIC BIOSENSORS | SUN, CAITLYN MINGYUN | 1795 | §103 | Non-Final OA | — | Pending | Mar 08, 2023 |
| 17936378 | Automatic classification of healthy and disease conditions from images or digital standard 12-lead ECGs | EVANISKO, GEORGE ROBERT | 3792 | §101 | Final Rejection | 26d | Pending | Sep 28, 2022 |
| 17780404 | MOLECULAR DATA STORAGE SYSTEMS AND METHODS | BAILEY, STEVEN WILLIAM | 1687 | §101§102§103§112 | Final Rejection | 30d overdue | Pending | May 26, 2022 |
| 17646648 | PASTE COMPRISING AMORPHOUS CALCIUM CARBONATE AND DRY 3D MODELS PREPARED THEREFROM | LING, DORIS | 1764 | §103 | Final Rejection | — | Pending | Dec 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTechnion Research & Development Foundation Limited has 31 pending office actions as of October 2026, spread across 31 art units and 31 examiners.
Virak Nguon has the most, with 1 of Technion Research & Development Foundation Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
